Skip to main content
. 2023 May 24;66(8):1431–1441. doi: 10.1007/s00125-023-05934-3

Table 1.

Characteristics of participants

Characteristic Part A Part B
Low dose (N=3) Medium dose (N=3) High dose (N=3) Placebo (N=5) ProTrans (N=10)
Age (years) 24±3 24±1 27±1 31±9 31±4
Sex (no. female/no. male) 0/3 0/3 0/3 3/2 4/6
Time since diagnosis (years) 1.1±0.0 1.1±0.1 0.8±0.7 1.0±0.3 1.0±0.7
Weight (kg) 75.1±10.4 80.2±8.1 75.7±2.7 67.5±12.6 73.9±9.3
BMI (kg/m2) 22.5±2.5 24.2±2.5 23.7±1.2 23.5±2.2 24.2±2.9

Data are presented as median ± SD